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Abstract
Background: Malaria kills almost 1 million people every year, but the mechanisms behind protective immunity against the
disease are still largely unknown.
Methodology/Principal Findings: In this study, surface plasmon resonance technology was used to evaluate the affinity
(measured as k
d) of naturally acquired antibodies to the Plasmodium falciparum antigens MSP2 and AMA1. Antibodies in
serum samples from residents in endemic areas bound with higher affinities to AMA1 than to MSP2, and with higher
affinities to the 3D7 allele of MSP2-3D7 than to the FC27 allele. The affinities against AMA1 and MSP2-3D7 increased with
age, and were usually within similar range as the affinities for the monoclonal antibodies also examined in this study. The
finding of MSP2-3D7 type parasites in the blood was associated with a tendency for higher affinity antibodies to both forms
of MSP2 and AMA1, but this was significant only when analyzing antibodies against MSP2-FC27, and individuals infected
with both allelic forms of MSP2 at the same time showed the highest affinities. Individuals with the highest antibody
affinities for MSP2-3D7 at baseline had a prolonged time to clinical malaria during 40 weeks of follow-up, and among
individuals who were parasite positive at baseline higher antibody affinities to all antigens were seen in the individuals that
did not experience febrile malaria during follow up.
Conclusions/Significance: This study contributes important information for understanding how immunity against malaria
arises. The findings suggest that antibody affinity plays an important role in protection against disease, and differs between
antigens. In light of this information, antibody affinity measurements would be a key assessment in future evaluation of
malaria vaccine formulations.
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Introduction
Malaria is a parasitic infection that threatens almost half of the
world’s population, with an estimated 243 million cases and
around 863,000 deaths in 2008 [1]. Individuals living in malaria-
endemic areas who do not die from the disease at a young age,
eventually develop immunity against the disease, but only slowly
and only after repeated exposure [2]. At a later stage, the
capability of controlling parasitemia in the blood is developed. The
mechanisms underlying development of anti-disease immunity and
the factors governing effective protection are still largely unknown.
However, it is well established that antibodies contribute to
protection against clinical malaria due to P. falciparum. Passive
transfer of immunoglobulins from immune donors to individuals
with P. falciparum infection reduced parasitemia and clinical
symptoms [3,4]. Antibodies directed against cell surface proteins
of either the merozoite form of the parasite or of infected red blood
cells have been shown to be important components of acquired
protective immunity against malaria [5].
In this study, we investigated the protective effect in humans of
antibodies against P. falciparum merozoite antigens, with a specific
goal of looking at whether the affinity of antibodies is of any
importance. The Merozoite Surface Protein 2 (MSP2) and Apical
Membrane Antigen 1 (AMA1) are well-characterized candidate
vaccine antigens and appear to be important immune targets
[5,6,7]. Therefore, these antigens were chosen to be included in
our study. MSP2 is an unusually hydrophilic protein and the
monomeric recombinant proteins are largely unstructured in
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merozoites, the parasite antigen is probably more structured [8,9].
This study was focused on the two main alleles of MSP2 (3D7 and
FC27), because nearly all P. falciparum isolates can be classified into
these two major groups. We also wanted to include a protein with
a more stable structure, and chose AMA1, which is stabilized by
eight intramolecular disulphide bonds [10,11] and is a type 1
integral membrane protein that is expressed in both sporozoite
and merozoite stages of the parasite [12,13].
Studies on acquired immunity to malaria including merozoite
proteins have mostly investigated antibodies to antigens in
standard immunoassays using recombinant proteins (eg. ELISA),
and there have been inconsistent associations between ELISA
results and protection from disease [14]. By eluting bound
antibodies with thiocyanate solutions of varying concentrations,
ELISA has been adapted to estimate relative antibody affinities
[15]. Using this method, trials in both mice and humans have
indicated that there are both low- and high affinity antibodies
acquired to malaria antigens [16,17].
The affinity or ‘functional affinity’ [18] of an antibody for its
corresponding antigen, has been modeled to be an important
determinant of the antibody’s biological efficacy [19,20] and it has
been frequently suggested that higher affinity antibodies are more
potent than lower affinity antibodies [21]. Also, excessive
production of low affinity antibodies has been considered as an
expression of immunodeficiency [22,23] and antibody affinity is
believed to be involved in the immunopathology of autoimmune
and immune complex diseases [20,24,25]. For other pathogens,
such as bacteria, it has been shown that affinity of antibodies is
important for protection from disease after vaccination [26,27].
Estimations of the affinity of antibodies in serum has been
limited, but with new methods based on surface plasmon
resonance, association and dissociation between antigen and
antibodies in a continuous flow can be studied in real time. This
method has proven to be of great value for evaluation of vaccine
design and efficacy studies for other pathogens [28]. In malaria,
SPR has mainly been used for evaluation of binding of monoclonal
antibodies [29,30,31].
The aim of this study was to increase the knowledge about the
mechanisms behind the development of antibody-mediated
protection against clinical malaria, by investigating whether there
are differences in affinity between naturally acquired antibodies
directed against different P. falciparum antigens, and whether
affinity is associated with protection from symptoms of malaria.
Affinity of an antibody is usually defined as a constant, KD
(dissociation constant) or KA (association constant), for a single
binding site at equilibrium. This can be calculated from
dissociation- and association rate constants obtained by kinetic
measurements. However, association rates are concentration
dependent and the concentrations of naturally acquired antibodies
in patient sera are difficult to measure, since the antibodies might
be directed against hundreds of different epitopes and the
concentration of each antibody can be very low. The restricted
volumes of the sera also make it difficult to purify antibodies to
high concentrations. We have therefore chosen to focus our studies
on measurement of dissociation rates (k
d), as an estimation of
affinity since this parameter is concentration independent and can
be measured directly in patient sera when using SPR. To have a
low dissociation rate is probably a prerequisite for an antibody to
be able to exert its function; if it comes off its target antigen too
quickly, it will not have time to inhibit for example merozoite
invasion. Since the sera can be used without purification, there is
no loss of antibodies and we believe that this is important for
including all varieties of polyclonal antibodies (both those of high
and low affinity) that are present in human sera. Also, since studies
on malaria immunity are performed in children and thus only
small sera volumes, purification of antibodies is difficult. In this
study, we used two representative P. falciparum antigens (MSP2 and
AMA1) for investigation of affinity (i.e. k
d) using human samples
and monoclonal antibodies. To evaluate the SPR method, we also
compared the results with standard ELISA and relative affinities
determined by ELISA with thiocyanate elution [32].
Materials and Methods
Reagents and genotyping
Surface plasmon resonance (SPR) measurements were per-
formed using a Biacore 3000 instrument, (Pharmacia Biosensor
AB, Uppsala) and all reagents including sensor chips CM5, amine
coupling kit containing N-hydroxysuccinimide [NHS), N-ethyl-N9-
[3-diethylaminopropyl) carbodiimide (EDC), ethanolamine hydro-
chloride and HBS-EP (10 mM Hepes (pH 7.4), 150 mM NaCl,
3 mM EDTA, 0.005% (v/v) polysorbate 20) running buffer, were
from Pharmacia Biosensor AB (Uppsala, Sweden). Sodium
acetate, ethylenediaminetetraacetate (EDTA) disodium salt, bo-
vine serum albumin (BSA), NH4SCN, and Tween20 were from
Sigma.
Genotyping of msp2 was performed using a nested PCR method
[33], to characterize whether parasites contained alleles of the
FC27 and/or 3D7/IC type.
Serum samples
Samples collected from P. falciparum exposed individuals in
Uganda and in Tanzania were analyzed in this study [34,35]. The
Ugandan samples (n=48) were collected in Apac in a study from
febrile children (6 months-5 years of age) with non-severe malaria
(parasitemia from 0.8–10%). The Tanzanian samples (n=171, age
1–74 years) were collected in a cross-sectional survey in March–
April 1999 within a longitudinal population study in Nyamisati,
Rufiji district, before the rainy season started. This area has
perennial transmission and some seasonal fluctuation. The overall
parasite prevalence was 27% and 46% by microscopy and PCR
respectively, with the highest prevalence (74% by PCR) observed
in children aged 3–5 years [34]. Malaria episodes were
continuously recorded through a passive case detection system in
which the villagers reported to the unit in the event of fever, for
diagnosis of malaria with microscopy, and free treatment. The
research unit also served as the only health station in the village.
All individuals with fever and Plasmodium parasites were treated
with sulphadoxine–pyrimethamine. In our study, we included only
individuals who were asymptomatic at baseline and had no record
of a clinical malaria episode 4 weeks before and 1 week after the
survey. All Tanzanian individuals had been tested HIV negative
and 77 individuals were P. falciparum positive by microscopy at
baseline. 55 individuals experienced an episode of malaria during
the 40 weeks of follow up (defined as cases), and for every case 2–3
age matched controls were selected among individuals without
episodes.
Ethics statement
Written informed consent was received from all subjects or their
guardians, and ethical permissions were granted for the studies
from National Institute for Medical Research in Tanzania,
Makerere University Faculty of Medicine Research and Ethics
Committee in Uganda, and the Stockholm Ethical Review Board
(permission numbers 03-095 for the Ugandan samples and 00-084
for the Tanzanian samples).
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Determination of anti-P. falciparum IgG antibody levels by
standard ELISA has been described for the Tanzanian cohort
[36]. Microtiter plates were coated with crude parasite antigen
solution (P. falciparum laboratory line F32, 20 mg/ml), and goat
anti-human IgG was used to detect IgG in the plasma samples.
IgG was isolated from sera using Protein G Sepharose 4 Fast
Flow (GE health care, Uppsala, Sweden), devoid of the albumin-
binding region.
For determination of antibodies against merozoite antigens,
ELISA plates (Maxisorb; NUNC 44-2404-21; Denmark) were
coated overnight with 1 mg/mL of purified recombinant protein in
coating buffer (15 mM Na2CO3 and 35 mM NaHCO3; pH 9.6),
blocked with 5% skimmed milk powder in 0.1 M phosphate
buffered saline (PBS) pH 7.4, washed 63 with 0.1% Tween/PBS
and then serum samples were added (1:100 dilution). After another
washing step, goat anti-human IgG ALP (Sigma A9544) was
applied, p-nitrophenyl phosphate tablets (Sigma N2765) used as a
substrate and OD measured at 405 nm. All sera were analyzed in
triplicate.
The sera were also tested for reactivity against His-tag
(Abbiotec, California) in Elisa. Hexa-His was coated on plates at
a concentration of 1 mg/well and then Elisa was run as above. The
sera showed no reactivity (not shown).
Proteins and Monoclonal antibodies
Recombinant MSP2-FC27 and MSP2-3D7 proteins with hexa-
His tags at the C-termini of the proteins, and the AMA1-D10
protein, with an N-terminal hexa-His tag, were expressed in E. coli
and purified by metal-chelation on a NTA resin and other
chromatography procedures [7,8]. AMA1-D10 contains the whole
ectodomain [37]; the D10 allele of AMA1 is very similar to 3D7
and is identical in domain I. The monoclonal antibodies (mAb)
were produced in Australia using standard procedures and spleen
cells from mice immunized with recombinant MSP2-3D7 and
AMA1-3D7. The MSP2 mAb 6D8 recognizes the conserved N-
terminal region. MAbs 9G8, 4D11, 6C9, 1F7, and 9H4 are
directed against epitopes in the conserved C-terminal region, and
mAbs 11E1, 2F2, and 9D11 recognize epitopes in the 3D7 family
specific region (Table 1). MAb 8G10, which recognizes an epitope
in the 32-mer repeat of MSP2-FC27, was provided by the
Queensland Institute of Medical Research. Three anti-AMA1
mAbs were included in the study; 1F9 recognizes a polymorphic
conformational epitope at one end of the solvent-exposed
hydrophobic trough on the AMA1 ectodomain [10], mAb 2C5
binds to the correctly folded ectodomain but the epitope has not
been mapped, and mAb 5G8 recognizes a linear epitope N-
terminal to the first conserved cysteine of the molecule [38]. All
monoclonal antibodies were diluted in HBS-EP running buffer.
Surface Plasmon Resonance
CM5 sensor chips were used together with N-terminal amine
coupling kits from Biacore to bind the proteins to the chip. The
carboxymethylated dextran surface of the chip was activated using
an injection pulse (10 min, 5 mL/min) containing a mixture of
0.05 M NHS and 0.05 M EDC. The protein was immobilized by
manual injection at 100 mg/mL in coating buffer (0.01 M sodium
acetate buffer, pH 4.0) until the desired response units were
achieved. Before coupling, an SDS-PAGE was run to confirm that
each protein consisted of a single band (data not shown). The
remaining sites on the sensor surface were blocked by injecting
50 mL of 1 M ethanolamine (pH 8.5) for 10 minutes. All steps
were carried out in a continuous flow of HBS-EP running buffer at
5 mL/min, and all buffers were degassed prior to use.
The SPR binding assays were performed with a constant flow
rate of 30 mL/min at 25uC. Serum samples (in different dilutions,
1:7.5, 1:15, 1:30, 1:60 or 1:90) or purified mAbs were flowed over
the bound recombinant proteins in HBS-EP buffer, pH 7.4. At all
dilutions, the association of antibodies with the immobilized
proteins was monitored for 3 minutes followed by 10 minutes of
dissociation. Residual bound antibody was removed by washing
the chip with 10 mM glycine-HCl (pH 1.5) for 5 seconds at 5 mL/
min. Reequilibration between the sensor surfaces and running
buffer was established prior to injection of the next sample.
Response was monitored as a function of time (sensogram) at
25uC. All SPR measurements were performed in at least two
different dilutions of sera. Kinetic parameters (k
a and k
d) were
evaluated by fitting the data using the BIAevaluation 4.1 software.
Ammonium thiocyanate ELISA
ELISA plates (as above) were coated with purified recombinant
protein (1 mg/mL) in coating buffer, blocked with 1% BSA/PBS,
washed 63 with 0.1% Tween/PBS and then serum samples
(1:100) were added followed by washing 63. NH4SCN was added
in different dilutions (0.0, 0.25, 0.5, 1.0, 2.0 and 3.5 M) and
incubated for 15 minutes at room temperature. After this, the
procedure was the same as above for the ELISA.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 5.0
software and R 2.13.0. To test for differences in mean affinity
between the recombinant proteins, an analysis of variance was
performed on the natural logarithm of the original measurements.
If there was evidence to reject the null hypothesis (no difference in
means), the Tukey Honestly Significant Differences test was used
for pair wise tests. For the Tanzanian samples, a binomial
regression was conducted to test whether a high affinity was
associated with the probability of getting malaria during follow up.
As independent variables we included a dichotomic variable
whether a malaria episode occurred within 40 weeks of follow up,
the affinities of each of the three recombinant proteins, and age.
To test if affinity was dependent on whether malaria occurred in
the years before the bleed, a normal linear regression was fitted to
the logarithm transformation of affinity using the protein type, the
mean number of malaria episodes per year, total number of
episodes before the bleed, and age as covariates. Segmented
Table 1. Binding sites for MSP2 monoclonal antibodies.
MSP2-Fc27 MSP2-3D7
6D8 N-term const N-term const
9G8 C-term const C-term const
4D11 C-term const C-term const
6C9 C-term const C-term const
1F7 C-term const C-term const
9H4 C-term const C-term const
8G10 Fc27 variable -
11E1 - 3D7 variable
2F2 - 3D7 variable
9D11 - 3D7 variable
Indication of binding sites for the MSP2 specific monoclonal antibodies.
Const=directed against constant regions of MSP2, variable=directed against
variable regions.
doi:10.1371/journal.pone.0032242.t001
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logarithmic transformation of the affinity to estimate the break-
point in age, that is, to determine whether the relationship
between age and affinity changed after a certain age. Where it was
not possible to determine a break-point, we fitted a normal linear
regression without break-points. The analysis was carried out
separately for each recombinant protein. Correlations were
calculated and tested as Spearman rank correlations. For all tests
two-tailed P values were considered significant if they were ,0.05,
and where models were fitted, residual plots were used to
determine the correctness of the model. To analyze the
importance of the presence of MSP2-3D7 or MSP2-FC27 parasite
genotypes in the blood, a normal linear regression was fitted to the
logarithmic transformation of the affinity. As covariates, we
included age, protein type, and two dichotomous variables, one
indicating the presence of parasites of the MSP2-3D7 type and the
other the presence of parasites of the MSP2-FC27 type. An
interaction of these two dichotomous variables was also added to
indicate whether none or both were found. Residual plots were
used to confirm the fulfillment of the conditions necessary for the
model.
Results
Contrasting affinities of antibodies to AMA1 and MSP2
Three recombinant merozoite antigens (MSP2-FC27, MSP2-
3D7 and AMA-D10) were immobilized through amine coupling to
CM5 surface plasmon resonance (SPR) sensor chips. The affinity
of antibodies in patient sera for these antigens was estimated using
dissociation rates (k
d) as described above, including a series of
different dilutions of the serum samples. We used Swedish non-
immune sera to determine the cut-off to be considered as
background level (=100 RU), and only samples that generated
binding data that were clearly discernable above background noise
were included in the subsequent analysis. The k
d values were
independent of the amounts of protein immobilized, demonstrat-
ing that the binding constants are independent of protein surface
density for the chosen concentrations. Very little or no binding was
detected for serum samples injected over the reference surface
(Figure 1). The dissociation rates were also independent of the
serum concentration used. In order to test the stability of the
recombinant proteins on the chip surface, a pool of sera (from
immune individuals) was used as an internal control after every 20
samples. The k
d values were independent of the loss of protein
over time (which was seen as a decrease in response units from
each surface). As a control, anti-IgG was added directly after the
serum samples for a subset of ten samples, to confirm the presence
of bound IgG to the recombinant proteins.
Human serum samples studied were obtained from two field
sites, one in Tanzania and the other in Uganda. The Tanzanian
samples came from 171 at baseline asymptomatic individuals
participating in a cross-sectional survey in a longitudinally
followed population, and the Ugandan samples from 48 children
with acute uncomplicated malaria. The Ugandan samples were
collected in an area with perennial holoendemic presence of
malaria with a very high transmission rate [39]. With these two
sets of samples, we could compare affinities of antibodies in
different areas, as well as different age groups and levels of disease
and endemicity. When a total of 219 samples were investigated,
significant differences (p-values,0.001) in affinity between the
proteins were observed, with antibodies to AMA1 having higher
affinity than antibodies to MSP2, as shown in Figure 2. In addition
antibodies to MSP2-3D7 had higher affinities than antibodies to
MSP2-FC27. The results were the same when each population
(Uganda or Tanzania) was analyzed separately and the same
pattern was seen for all age groups. The differences were
significant both when the antigens were individually compared
to each other, and when the comparisons were made across all
three antigens. Out of 219 samples tested, 90% had measurable
responses in SPR for MSP2-3D7, 83% for MSP2-FC27 and 90%
for AMA1-D10. No common factors (such as age) could be found
for the samples that did not have measurable responses. The
samples that had enough response to be classified as significant
binding usually reached levels of Response Units of several
hundreds-to-thousands within the three minutes used for our
experiments (see, for example, Figure 1), indicating that the
association rates were relatively fast for all samples. To establish
that the effects of whole serum binding to recombinant proteins on
Figure 1. SPR Sensogram for one representative plasma
sample. A sensogram showing association and dissociation of a
representative serum sample to recombinant MSP2-FC27, MSP2-3D7
and AMA1-D10 (Fc2, Fc3 and Fc4, respectively). Fc1 was used as blank
to control for non-specific binding.
doi:10.1371/journal.pone.0032242.g001
Figure 2. Affinity measured as k
d in 219 individuals. Pattern of
affinity response (measured as k
d values) of exposed sera (n=219)
against recombinant proteins coupled to an SPR-chip. The increasing
affinity (equals lower kd values) was observed in the order of MSP2-
FC27, MSP2-3D7 and AMA1-D10 and the differences were statistically
significant (p,0.0001), both when the individual proteins were
compared to each other and compared across all three antigens
(ns=p.0.05; *=p,0.05; **=p,0.01; ***=p,0.001). The box plot
values represent the 25
th percentile, median, and the 75
th percentile.
The whisker range is between the 5th and 95th percentiles.
doi:10.1371/journal.pone.0032242.g002
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purified from 5 of the Tanzanian samples (from individuals aged
12–51 years, 3 P. falciparum positive and 2 P. falciparum negative by
microcopy at baseline) and tested against MSP2-3D7 and MSP2-
FC27. There were no significant differences between the k
d values
obtained with purified IgG samples and the corresponding whole
sera (data not shown), indicating that the majority of the measured
effect was due to antibodies present in serum that specifically
bound to the immobilized antigens.
The affinities of antibodies in serum samples were compared to
the affinities of sets of mAbs directed against AMA1 and MSP2.
Initially, we analyzed the affinities of mAbs 1F9, 2C5 and 5G8
when binding to AMA1-D10 on the SPR-chip. 1F9 was found to
bind with very high affinity (k
d=6.2610
26), while 2C5 and 5G8
showed lower affinities (k
d=4.2610
24 for 2C5, and
k
d=9.2610
24 for 5G8). We also analyzed several mAbs against
MSP2 (Table 1, Figure 3), and found that when the k
d values for
the mAbs against both AMA1 and MSP2 were compared with
those found in patient sera, they were similar, except for 1F9
which showed a very high affinity. For the MSP2 proteins, the
mAbs 9G8, 1F7 and 9H4 (directed against the conserved C-
terminal region) exhibited slightly higher affinity for the 3D7 allele
compared to the FC27 allele, as did also mAb 6D8 directed
against the N-terminal conserved region although this mAb had a
lower affinity in general. The mAbs 9D11 and 8G10, directed
against the variable regions of MSP2-3D7 and MSP2-FC27,
respectively, had relatively low affinities while mAb 2F2, directed
against the variable region of MSP2-3D7 had a higher affinity.
The affinity of 4D11, directed against the conserved C-terminal
region, was too low to measure, as was also mAb 11E1, directed
against the variable region of MSP2-3D7.
To evaluate the effect of different mixtures of antibodies, ten
different serum samples (selected because we had relatively large
volumes of these) were analyzed using SPR and the MSP2-FC27
protein. The individual k
d values ranged from 3.3610
25 to
7.8610
24 s
21. The theoretically calculated mean for these
samples was 2.9610
24, (median 2.3610
24) but when an equal
mixture of all ten samples was studied, the measured k
d value was
1.6610
24 s
21. This indicates that when antibodies are mixed,
such as for example in serum, the values measured are
representatives of the mixtures of antibodies, and not only a
representation of one dominating high-affinity antibody. When an
analogous experiment was performed with mixtures of mAbs, the
results were similar. For example, the individual k
d values for the
mAb 9G8 and 6D8 against MSP2-3D7 were 1.30610
25 and
1.15610
24 s
21 respectively, whereas the 50:50 mixture of these
antibodies produced a k
d value of 5.73610
25 s
21. The mAb 6C9
had an individual k
d value for binding to MSP2-3D7 of
1.34610
25, while a mixture of 25% 6C9 and 75% 6D8 gave a
k
d value of 7.12610
25 s
21, and 75% 6C9 and 25% 6D8 gave
1.35610
25 s
21.
Correlation between affinity and ELISA results
To compare the affinity of the antibodies in serum samples to
total IgG/IgM as estimated by ELISA, we used the recombinant
proteins for both SPR with a continuous flow of sera containing
the antibodies, and standard ELISAs, for a subset of samples.
Initially, the 48 sera collected from children in Uganda (6 months–
5 years of age) with mild malaria were used. These samples were
selected for comparative studies, since we had relatively high
volumes of these samples. 44 sera gave measurable responses for
all antigens in SPR and were therefore used also for ELISA
studies. All the 44 samples were also positive in ELISA assays for
all antigens. No significant correlation was seen between standard
IgG ELISA and SPR results for the MSP2 proteins (Spearman
correlation coefficient 20.22 for MSP2FC27 and 20.25 for
MSP23D7), however the IgG ELISA values correlated with SPR
for the AMA1-D10 (Spearman correlation coefficient 20.37,
p=0.01). When standard IgM ELISA was compared to SPR
assays for all three proteins, there were no significant correlations.
The samples from Uganda were all from symptomatic children
with P. falciparum malaria. When the comparison between IgG
schizont extract ELISA [34] and SPR data was performed on the
Tanzanian cohort where all the samples were from asymptomatic
individuals, we found no correlation between P falciparum specific
IgG and our SPR data generated with the recombinant proteins.
Effect of age and concurrent infection on antibody
affinity and ELISA results
Since protection against malaria is often associated with older
age in endemic areas, we wanted to know how affinity of the
antibodies developed with age. A segmented regression analysis
was used for the sera from Tanzanian individuals, where we had
access to a relatively large number of samples (n=171) of
different ages (1–74 years) to estimate a possible break-point for
age in terms of affinity. For AMA1, the affinity increased until 16
years of age where there was a breakpoint after which affinity
values were stable (p,0.01, Figure 4). For MSP2-3D7 no
breakpoint could be determined, but a slight increase in affinity
with age could be seen when all ages were considered together
(p,0.05). For MSP2-FC27, no significant changes in affinity with
age could be seen.
For P. falciparum (prepared as schizont extract) specific IgG there
was a significant increase with age (p,0.0001) in the Tanzanian
sera [34]. For the samples from symptomatic children in Uganda
(aged 6 months–5 years), no significant correlations between age
and IgG ELISA could be seen for the MSP2 proteins (each protein
was analyzed separately), but for AMA1-D10 there was a
significant correlation between IgG and age (p,0.0001, Spearman
correlation coefficient 0.64).
Figure 3. kd values for monoclonal antibodies against MSP2.
Comparison of affinity response of the mAbs against recombinant
MSP2-FC27 and MSP2-3D7 proteins. The error bars indicate mean 6
SEM.
doi:10.1371/journal.pone.0032242.g003
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The Tanzanian samples were from asymptomatic individuals of
all ages who were followed prospectively with regards to febrile
episodes and malaria. These samples were therefore used for
further analysis of associations between affinity, IgG ELISA results
and protection from malaria. When the time to the next clinical
episode of malaria from baseline was assessed it was found that the
17 individuals having the top 10% of the highest affinity antibodies
(out of 171 samples) against MSP2-3D7 (mean kd 1.10610
24) had
a longer duration (mean 37 weeks) to clinical malaria when
compared with individuals with the 10% lowest affinity antibodies
(mean kd 9.10610
24, duration 25 weeks, p,0.0001). High affinity
against MSP2-FC27 or AMA1-D10 did not correlate with longer
time to disease. We also analyzed whether there was any
association between how many times the individuals had malaria
in the years before the survey and affinity for the different
antigens, but could not find any associations (either as episodes per
year or as total number of episodes). The individuals were then
divided into two groups: those that had parasites in the blood at
the time of sampling, and those that were parasite negative, similar
to approaches used in other studies [40] because parasitemia has
been associated with antibody levels. Further, the samples were
subdivided into those in whom malaria was diagnosed within 40
weeks of follow up, and those who did not develop malaria. There
was no significant difference in P. falciparum specific IgG between
malaria prone and protected individuals (whether analyzed as
parasite positive and negative separately, or all samples together,
and including adjustment for age). In contrast, among individuals
who were parasite positive at baseline (n=77), higher antibody
affinities to all antigens were seen in the individuals who not
experience febrile malaria during follow up (Figure 5, p,0.01 for
MSP2-FC27, p,0.05 for MSP2-3D7 and p,0.03 for AMA1-
D10), suggesting that high affinity may be important for protection
against disease. In the parasite negative group, no differences in
affinity could be seen between malaria prone and protected
individuals.
The importance of allelic variant present in the blood
We investigated whether it made a difference in affinity which
P. falciparum MSP2 genotypes were present in the blood of the
individuals at the time of sample collection in the Tanzanian
cohort (Figure 6). 39 individuals were infected with parasites of
both the 3D7 and FC27 MSP2 alleles, 28 had only the 3D7 allele
Figure 5. Association between affinity (measured as k
d) and
protection from clinical malaria. Affinity versus protection for the
individuals in the Tanzanian population that were P. falciparum positive
(n=77). Individuals with high affinity had lower risk of developing
malaria during follow-up (No malaria=did not get malaria within 40
weeks, Malaria=Experienced a clinical episode of malaria during follow
up). Fc27 and 3D7 indicates the recombinant MSP2 proteins used in the
SPR assay. (Box plots representations as in Figure 2.)
doi:10.1371/journal.pone.0032242.g005
Figure 4. Natural logarithm of k
d variation with age in the
Tanzanian population. Affinity variation with age for samples from
Tanzania, shown for binding to AMA1-D10 where the break-point was
determined to be 16 years of age. The solid line is the estimated fit from
the linear normal model. The red dot with a line at the bottom indicates
the 95% confidence interval for the breakpoint.
doi:10.1371/journal.pone.0032242.g004
Figure 6. Presence of specific alleles of parasites in the blood
associated with different affinities. Affinity of Tanzanian serum
samples depending on which allele of MSP2 parasite was present in the
blood at the time of collection. Presence of both alleles of MSP2 is
associated with the highest affinity of antibodies in the sera, and that
presence of the 3D7 allele was associated with higher affinity compared
to the Fc27 allele. The error bars indicate mean 6 SEM, and the asterisks
indicate the level of significant differences (ns=p.0.05; *=p,0.05;
**=p,0.01; ***=p,0.001).
doi:10.1371/journal.pone.0032242.g006
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target protein in the SPR analysis higher antibody affinities were
seen in individuals infected with parasites having the 3D7 MSP2
allele (p,0.03), and with parasites of both MSP2 genotypes in the
blood at the time of sample collection (p,0.005). These results
reached significance only when antibodies against MSP2-FC27
were used in the SPR analysis, and the results obtained using
MSP2-3D7 or AMA1-D10 as target proteins showed a compara-
ble trend. Similar observations were made with the Ugandan
samples in which presence of 3D7 allele was associated with higher
affinity for all antigens, but only reached significance using MSP2-
FC27 as the target.
Comparison of methods
Since SPR analysis is a relatively new method for investigating
affinity of antibodies in serum, we performed a comparative
analysis of SPR and ammonium thiocyanate ELISA for the
samples from Ugandan children (these samples were used since we
had relatively large volumes of them) using the recombinant
MSP2-FC27 and 3D7 proteins. The ammonium thiocyanate
ELISA was performed as an ELISA (measuring IgG) but with
addition of increasing concentrations of ammonium thiocyanate.
No correlation was seen between SPR and ammonium thiocya-
nate ELISA, but a correlation was observed between standard IgG
ELISA and ammonium thiocyanate ELISA for both MSP2-FC27
and MSP2-3D7 (p,0.0001 for both, Spearman correlation
coefficient 0.66 and 0.70, respectively).
Discussion
We have investigated affinity (measured as k
d) of naturally
acquired antibodies in serum against two important immune
targets and leading P. falciparum blood-stage vaccine candidates,
AMA1 and MSP2. We found that high affinity against either of
the antigens (although significant only among individuals who
were parasite positive at baseline) was associated with protection
from experiencing disease during follow up in a high endemic area
in Tanzania. Moreover, the individuals with the highest affinities
against MSP2-3D7 had longer time to next episode of malaria.
Affinity increased with age for AMA1 and MSP2-3D7. This
indicates that affinity is important for development of protection
against malaria, and also that affinity needs to be taken into
consideration when evaluating new vaccine candidates. A
protective effect of affinity could not be seen in individuals who
were parasite negative at baseline; this might be because our study
population was too small to make the differences significant, or
because the exposure to parasites in general was lower in the
parasite negative group.
When P. falciparum IgG was measured in a standard ELISA, it
was not associated with protection, even though the levels of
antibodies increased with age. This supports the idea that function
and not only presence of antibodies is important for protection
against malaria. It might be that affinity increases with increased
exposure to malaria, but since there were such clear differences
between different antigens and the results were adjusted for age,
and because there was very little correlation between ELISA
results (which are often considered to be associated with exposure
[41]) and affinity, we think that an evaluation of protection against
malaria should include a consideration of antibody affinity.
In both populations studied antibodies to AMA1 were of higher
affinity than antibodies to MSP2. In the area in Uganda,
transmission rates are extremely high and the samples were from
febrile children. In Tanzania, the area has some seasonal
fluctuations in malaria transmission and the samples were from
individuals without symptoms. In spite of these dissimilarities, the
affinity patterns towards AMA1 and MSP2 proteins were the
same. The differences in affinities could be related to different
structural characteristics of these two antigens. AMA1, which is
conserved throughout the Plasmodium genus and in other
apicomplexan parasites, has globular domains stabilized by
intramolecular bonds [11,42]. In contrast, MSP2, which lacks
orthologues in most Plasmodium species, is an intrinsically
unstructured protein [8,43], which could potentially result in
relatively low affinity antibodies [44]. High affinity antibodies
result from the selection by antigen of relatively rare B cells in
which the process of somatic hypermutation (with the help of
follicular T helper cells) generates B-cell receptors that bind
antigen with higher affinity. The increased affinity of the matured
antibody response for conventional antigens reflects an improved
fit between antigen and antibody so that affinity is not limited by
the entropic cost of conformational changes in the antibody
complementarity determining regions, which are a characteristic
of the induced fit interactions of antibodies in the naı ¨ve repertoire
[45,46]. When unstructured proteins bind target ligands, they
usually adopt a more ordered conformation [47] and we assume
that MSP2 would undergo similar transitions when binding to
many antibodies. The entropic cost of these transitions could limit
the affinity of MSP2-antibody interactions irrespective of how
effectively the process of somatic hypermutation generated high
affinity anti-MSP2 antibodies.
The different alleles of MSP2 can be categorized into two major
groups, 3D7 and FC27, based on differences in repeats and
flanking variable sequences [48,49,50]. Parasites of both allelic
types have been shown to be present in Tanzanian and Ugandan
populations, although the 3D7 allele appears to be slightly more
common [34,51,52,53]. It was noted that both human polyclonal
antibodies and several of the mAbs directed against conserved
regions of MSP2 bound with higher affinity to MSP2-3D7 than to
MSP2-FC27. It might be that the FC27 form of MSP2 has a lower
propensity to adopt the more structured conformation required for
some of the antibodies to bind, but it could also be that higher
exposure to the 3D7 allele has resulted in formation of higher
affinity antibodies.
We noted that the presence of parasites of the 3D7 type in the
blood correlated with higher affinity of all antibodies (even though
it reached significance only for antibodies to MSP2-FC27), and
that high affinity towards the 3D7 allele correlated with longer
time to next infection, further strengthening the importance of the
3D7 allele. This is very important knowledge for future vaccine
studies, showing that one of the most critical parameters for the
outcome of the study may be which allelic form of a protein the
vaccine is based on. These results are in line with older studies
where strain-specificity for MSP2 was noted to be of importance
for formation of a protective response (even though the protection
was very modest) [54], and where a higher prevalence of 3D7-
specific antibodies was found in children with asymptomatic
malaria and a higher prevalence of FC27-specific antibodies was
found in children with clinical malaria [55]. Our findings are also
important for understanding how development of protection
against malaria arises; if particular allelic forms of antigens
generate higher affinity antibodies, the rate at which protection
against disease develops may vary depending on which parasite
genotypes are encountered.
For AMA1, several polymorphisms have been described. In our
studies, only the D10 form of AMA1 was used and different results
may have been obtained if another form of this antigen had been
used. However, there are descriptions in the literature of
antibodies that bind to several variants of AMA1 [56], and even
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P. falciparum examined [29]. We could conclude that most of our
tested sera were positive for antibodies against AMA1, indicating
that either the used strain is common in the population, or that it
can cause development of cross-reactive antibodies against AMA1.
It is difficult to speculate what the result would have been if other
strains had been used, but our results show that there is at least one
strain that can generate high-affinity antibodies in patients, which
strengthens the potential use of AMA1 as a vaccine candidate.
We have used the dissociation rate constant, k
d, as an indicator
of affinity, because determination of k
d is not reliant on knowledge
of the concentration of the antibodies, which is difficult to assess in
polyclonal samples [26]. Judging from the levels of Response Units
achieved within just a few minutes of binding between antibody
and antigen, the association phase of binding was in general very
effective, indicating that the antibodies may be functional in for
example binding to merozoites, which are only accessible to
antibodies for a short time. It has been suggested that antibodies
would need to exist at high concentration to be effective in
inhibiting merozoite invasion due to this kinetic constraint and
antibody affinity would be of less importance [57]. However, the
importance of affinity for activity in inhibiting merozoite invasion
was shown in a study with anti-AMA1 shark antibodies (IgNARs)
[58]. In this study mutagenesis of an IgNAR resulting in an
increase in the affinity for AMA1 (a decreased dissociation rate but
little change in the association rate) was associated with an increase
in the merozoite invasion inhibitory activity. Also, in vivo, binding
of one antibody might slow down the invasion process, allowing
more time for other antibodies to bind, causing relatively low
concentrations of several antibodies to become functionally
important. In future studies, we intend to measure dissociation
rates against antigens on the infected erythrocyte surface, to
establish whether high affinity is something that is developed in an
individual at a certain stage of immunity, or whether it is different
and specific for each antigen that an individual is exposed to.
We could show that the affinity range (measured as k
d) in the
sera was similar to that for monoclonal antibodies, with the
exception that mAb 1F9 bound to AMA1-D10 with very high
affinity. mAb 1F9 has previously been shown to have a very large
binding surface area [38], which no doubt helps in creating a
stable complex. 1F9 is known to inhibit invasion, but 2C5 and
5G8 (which are also directed against AMA1) do not. This could be
because 1F9 binds a neutralizing epitope, but as 2C5 and 5G8
bind AMA1 with about a hundred times lower affinity than 1F9,
affinity may be important for antibody function in the growth
inhibition assay, as has also been shown in studies with AMA1-
binding shark antibodies [58]. It has been shown before that
function and not only presence of antibodies is important in
malaria [59]. In further studies, we will compare affinity to
invasion inhibition and see whether these relate to each other.
Our results from the SPR studies are the total result of
measurement of a polyclonal response, and we could show that
our measurements are the sum of binding of many different
antibodies by mixing different sera and different mAb. There
might have been a low concentration of very high affinity
antibodies in the sample that we could not detect, but if there at
the same time was a high concentration of lower affinity
antibodies, the net effect would probably still be that the binding
was weaker with antibodies coming off the target protein more
quickly. It has been shown before that mixing of different
antibodies can affect the total outcome of the function of the
antibody [60].
In this study, we also wanted to evaluate different methods for
measurement of antibodies. ELISA measures the presence or
absence of antibodies in a static system, while SPR measures the
strength of the interaction during flow. For AMA1, which bound
antibodies with high affinity, we could see a correlation between
standard IgG ELISA and SPR methods. This might be because
high affinity antibodies are not washed away during handling of
the ELISA plate. This would be in line with the fact that we could
see a correlation between the MSP2 proteins binding in standard
ELISA and in NH4SCN ELISA, as these methods are much more
similar to each other than to SPR. When NH4SCN ELISA assays
have been used in malaria research before, either for evaluation of
affinities after vaccination or after natural infection, the results
have often failed to show consistent patterns [61,62], indicating
that other means of measuring affinity is needed.
In conclusion, we have demonstrated a new way of evaluating
antibodies in malaria, using SPR for measurement of affinity in
polyclonal responses against different proteins. We have shown
that high affinity correlated with longer time to infection during
follow-up for MSP2-3D7. Further, the presence in the blood of
parasites expressing particular alleles of the antigen was associated
with higher affinity antibodies. This information is important for
understanding how immunity against malaria arises, and for
selection of future vaccine candidates.
Acknowledgments
We thank E Refai and H Jo ¨rnvall for use of the Biacore, and we are
grateful to all participants in the studies. We thank Dr Ingegerd Rooth for
the sample collection and longitudinal follow up in Tanzania. We thank
Johan Normark and Ulf Ribacke for the collection of samples in Uganda.
Author Contributions
Conceived and designed the experiments: SR KP. Performed the
experiments: SR KP. Analyzed the data: SR JB RA AF SL SKB MW
KP. Contributed reagents/materials/analysis tools: FK. Wrote the paper:
SR KP.
References
1. World Health Organization (2009) World Malaria Report 2009. Geneva,
Switzerland: World Health Organization.
2. Marsh K, Kinyanjui S (2006) Immune effector mechanisma in malaria. Parasite
Immunol 28: 51–60.
3. Hommel M, Semoff S (1988) Expression and function of erythrocyte-associated
surface antigens in malaria. Biol Cell 64: 183–203.
4. Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S,
et al. (2001) Contribution of humoral immunity to the therapeutic response in
falciparum malaria. Am J Trop Med Hyg 65: 918–923.
5. Richards JS, Beeson JG (2009) The future for blood-stage vaccines against
malaria. Immunol Cell Biol 87: 377–390.
6. Genton B, Betuela I, Felger I, Al Yaman F, Robin AF, et al. (2002) A
Recombinant Blood Stage Malaria Vaccine Reduces Plasmodium falciparum
Density and Exerts Selective Pressure on Parasite Populations in a Phase 1 & 2b
Trial in Papua New Guinea. J Infect Dis 185: 820–827.
7. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, et al. (2005) A human
phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine
candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine
23: 3076–3083.
8. Adda CG, Murphy VJ, Sunde M, Waddington LJ, Schloegel J, et al. (2009)
Plasmodium falciparum merozoite surface protein 2 is unstructured and forms
amyloid-like fibrils. Mol Biochem Parasitol 166: 159–171.
9. Yang X,Adda CG, Keizer DW, Murphy VJ, Rizkalla MM, et al. (2007) A partially
structured region of a largely unstructured protein, Plasmodium falciparum merozoite
surface protein 2 (MSP2), forms amyloid-like fibrils. J Pept Sci 13: 839–848.
10. Coley AM, Gupta A, Murphy VJ, Bai T, Kim H, et al. (2007) Structure of the
Malaria Antigen AMA1 in Complex with a Growth-Inhibitory Antibody. PLoS
Pathog 3: e138.
11. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, et al. (2005) Structure of
AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that
Affinity of Antibodies in Malaria
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e32242surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A 102:
12736–12741.
12. Narum DL, Thomas AW (1994) Differential localization of full-length and
processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium
falciparum merozoites. Mol Biochem Parasitol 67: 59–68.
13. Silvie O, Franetich J-F, Charrin S, Mueller MS, Siau A, et al. (2004) A Role for
Apical Membrane Antigen 1 during Invasion of Hepatocytes by Plasmodium
falciparum Sporozoites. J Biol Chem 279: 9490–9496.
14. Fowkes FJI, Richards JS, Simpson JA, Beeson JG (2010) The Relationship
between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum
Malaria: A Systematic Review and Meta-analysis. PLoS Med 7: e1000218.
15. Pullen GR, Fitzgerald MG, Hosking CS (1986) Antibody avidity determination
by ELISA using thiocyanate elution. J Immunol Meth 86: 83–87.
16. Ray P, Sahoo N, Singh B, Kironde FA (1994) Serum antibody immunoglobulin
G of mice convalescent from Plasmodium yoelii infection inhibits growth of
Plasmodium falciparum in vitro: blood stage antigens of P. falciparum involved
in interspecies cross-reactive inhibition of parasite growth. Infect Immun 62:
2354–2361.
17. Demanga CG, Daher L-J, Prieur E, Blanc C, Perignon J-L, et al. (2010) Toward
the Rational Design of a Malaria Vaccine Construct Using the MSP3 Family as
an Example: Contribution of Antigenicity Studies in Humans. Infect Immun 78:
486–494.
18. Karush F (1970) Affinity and The Immune Response. Ann New York Acad Sci
169: 56–64.
19. Iber D (2001) Affinity Maturation in the Immune System. Oxford: Oxford
University. 230 p.
20. Steward MW, Steensgaard J (1983) Antibody affinity: Thermodynamic aspects
and biological significance. Raton Boca. Fla.: CRC Press. 170 p.
21. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, et al. (2007) Regulation
of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent
Affinity for Target Antigen. J Immunol 179: 2815–2823.
22. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, et al. (2006) Low Avidity and
Level of Serum Anti-A[beta] Antibodies in Alzheimer Disease. Alz Dis & Assoc
Disord 20: 127–132.
23. Soothill JF, Steward MW (1971) The immunopathological significance of the
heterogeneity of antibody affinity. Clin Exp Immunol 9: 193–199.
24. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler A-G, et al. (2004)
Mature high-affinity immune responses to (pro)insulin anticipate the autoim-
mune cascade that leads to type 1 diabetes. J Clin Invest 114: 589–597.
25. Shimizu F, Mossmann H, Takamiya H, Vogt A (1978) Effect of antibody avidity
on the induction of renal injury in anti-glomerular basement membrane
nephritis. Br J Exp Pathol 59: 624–629.
26. Breukels Mijke A, Zijde Els MJ-van d, van Tol Maarten JD, Rijkers Ger T
(2002) Concentration and Avidity of Anti-Haemophilus influenzae Type b (Hib)
Antibodies in Serum Samples Obtained from Patients for Whom Hib
Vaccination Failed. Clin Infect Dis 34: 191–197.
27. Goldblatt D, Vaz AR, Miller E (1998) Antibody avidity as a surrogate marker of
successful priming by Haemophilus influenzae type b conjugate vaccines following
infant immunization. J Infect Dis 177: 1112–1115.
28. Hearty S, Conroy PJ, Ayyar BV, Byrne B, O’Kennedy R (2010) Surface
plasmon resonance for vaccine design and efficacy studies: recent applications
and future trends. Exp Rev Vacc 9: 645–664.
29. Igonet S, Vulliez-Le Normand B, Faure G, Riottot M-M, Kocken CHM, et al.
(2007) Cross-reactivity Studies of an Anti-Plasmodium vivax Apical Membrane
Antigen 1 Monoclonal Antibody: Binding and Structural Characterisation. J Mol
Biol 366: 1523–1537.
30. Plassmeyer ML, Reiter K, Shimp RL, Jr., Kotova S, Smith PD, et al. (2009)
Structure of the Plasmodium falciparum circumsporozoite protein, a leading
malaria vaccine candidate. J Biol Chem 284: 26951–26963.
31. Uthaipibull C, Aufiero B, Syed SEH, Hansen B, Patin ˜o JAG, et al. (2001)
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface
protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 307:
1381–1394.
32. MacDonald RA, Hosking CS, Jones CL (1988) The measurement of relative
antibody affinity by ELISA using thiocyanate elution. J Immunol Meth 106:
191–194.
33. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, et al. (1999) Biased
distribution of msp1 and msp2 allelic variants in Plasmodium falciparum
populations in Thailand. Trans Royal Soc Trop Med Hyg 93: 369–374.
34. Bereczky S, Liljander A, Rooth I, Faraja L, Granath F, et al. (2007) Multiclonal
asymptomatic Plasmodium falciparum infections predict a reduced risk of malaria
disease in a Tanzanian population. Microb Infect 9: 103–110.
35. Normark J, Nilsson D, Ribacke U, Winter G, Moll K, et al. (2007) PfEMP1-
DBL1a amino acid motifs in severe disease states of Plasmodium falciparum
malaria. Proc Natl Acad Sci U S A 104: 15835–15840.
36. Bereczky S, Montgomery SM, Troye-Blomberg M, Rooth I, Shaw M-A, et al.
(2004) Elevated anti-malarial IgE in asymptomatic individuals is associated with
reduced risk for subsequent clinical malaria. Intern J Parasitol 34: 935–942.
37. Hodder AN, Crewther PE, Anders RF (2001) Specificity of the Protective
Antibody Response to Apical Membrane Antigen 1. Infect Immun 69:
3286–3294.
38. Coley AM, Campanale NV, Casey JL, Hodder AN, Crewther PE, et al. (2001)
Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium
falciparum AMA1 by combined phage display of fragments and random peptides.
Protein Eng 14: 691–698.
39. Proietti C, Pettinato DD, Kanoi BN, Ntege E, Crisanti A, et al. (2011)
Continuing Intense Malaria Transmission in Northern Uganda. Am J Trop Med
Hyg 84: 830–837.
40. Polley SD, Mwangi T, Kocken CHM, Thomas AW, Dutta S, et al. (2004)
Human antibodies to recombinant protein constructs of Plasmodium falciparum
Apical Membrane Antigen 1 (AMA1) and their associations with protection from
malaria. Vaccine 23: 718–728.
41. Richards JS, Stanisic DI, Fowkes FJI, Tavul L, Dabod E, et al. (2010)
Association between Naturally Acquired Antibodies to Erythrocyte-Binding
Antigens of Plasmodium falciparum and Protection from Malaria and High-
Density Parasitemia. Clin Infect Dis 51: e50–e60.
42. Chesne-Seck ML, Pizarro JC, Vulliez-Le Normand B, Collins CR,
Blackman MJ, et al. (2005) Structural comparison of apical membrane antigen
1 orthologues and paralogues in apicomplexan parasites. Mol Biochem Parasitol
144: 55–67.
43. Zhang X, Perugini MA, Yao S, Adda CG, Murphy VJ, et al. (2008) Solution
Conformation, Backbone Dynamics and Lipid Interactions of the Intrinsically
Unstructured Malaria Surface Protein MSP2. J Mol Biol 379: 105–121.
44. Anders RF (1986) Multiple cross-reactivities amongst antigens of Plasmodium
falciparum impair the development of protective immunity against malaria.
Paras Immunol 8: 529–539.
45. Manivel V, Sahoo NC, Salunke DM, Rao KVS (2000) Maturation of an
Antibody Response Is Governed by Modulations in Flexibility of the Antigen-
Combining Site. Immunity 13: 611–620.
46. Wong SE, Sellers BD, Jacobson MP (2011) Effects of somatic mutations on CDR
loop flexibility during affinity maturation. Proteins 79: 821–829.
47. Dyson HJ, Wright PE (2005) Intrinsically unstructured proteins and their
functions. Nat Rev Mol Cell Biol 6: 197–208.
48. Engelbrecht F, To ¨gel E, Beck H-P, Enwezor F, Oettli A, et al. (2000) Analysis of
Plasmodium falciparum infections in a village community in Northern Nigeria:
determination of msp2 genotypes and parasite-specific IgG responses. Acta Trop
74: 63–71.
49. Smythe JA, Peterson MG, Coppel RL, Saul AJ, Kemp DJ, et al. (1990)
Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium
falciparum. Mol Biochem Parasitol 39: 227–234.
50. Thomas AW, Carr DA, Carter JM, Lyon JA (1990) Sequence comparison of
allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. Mol
Biochem Parasitol 43: 211–220.
51. Henning L, Schellenberg D, Smith T, Henning D, Alonso P, et al. (2004) A
prospective study of Plasmodium falciparum multiplicity of infection and
morbidity in Tanzanian children. Trans Royal Soc Trop Med Hyg 98: 687–694.
52. Mwingira F, Nkwengulila G, Schoepflin S, Sumari D, Beck H-P, et al. (2011)
Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in
sub-Saharan Africa. Malaria J 10: 79.
53. Peyerl-Hoffmann G, Jelinek T, Kilian A, Kabagambe G, Metzger WG, et al.
(2001) Genetic diversity of Plasmodium falciparum and its relationship to
parasite density in an area with different malaria endemicities in West Uganda.
Trop Med & Intern Health 6: 607–613.
54. Genton B, Betuela I, Felger I, Al Yaman F, Robin AF, et al. (2002) A
Recombinant Blood Stage Malaria Vaccine Reduces Plasmodium falciparum
Density and Exerts Selective Pressure on Parasite Populations in a Phase 1 & 2b
Trial in Papua New Guinea. J Infect Dis 185: 820–827.
55. Taylor R, Allen S, Greenwood B, Riley E (1998) IgG3 antibodies to Plasmodium
falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age
and association with clinical immunity to malaria. Am J Trop Med Hyg 58:
406–413.
56. Kusi KA, Faber BW, Thomas AW, Remarque EJ (2009) Humoral Immune
Response to Mixed PfAMA1 Alleles; Multivalent PfAMA1 Vaccines Induce
Broad Specificity. PLoS ONE 4: e8110.
57. Saul A (1987) Kinetic constraints on the development of a malaria vaccine. Paras
Immunol 9: 1–9.
58. Henderson KA, Streltsov VA, Coley AM, Dolezal O, Hudson PJ, et al. (2007)
Structure of an IgNAR-AMA1 Complex: Targeting a Conserved Hydrophobic
Cleft Broadens Malarial Strain Recognition. Structure 15: 1452–1466.
59. Persson KEM, McCallum FJ, Reiling L, Lister NA, Stubbs J, et al. (2008)
Variation in use of erythrocyte invasion pathways by Plasmodium falciparum
mediates evasion of human inhibitory antibodies. J Clin Invest 118: 342–351.
60. Guevara Patino JA, Holder AA, McBride JS, Blackman MJ (1997) Antibodies
that Inhibit Malaria Merozoite Surface Protein-1 Processing and Erythrocyte
Invasion Are Blocked by Naturally Acquired Human Antibodies. J Exp Med
186: 1689–1699.
61. Bargieri DY, Rosa DS, Lasaro MA, Ferreira LC, Soares IS, et al. (2007)
Adjuvant requirement for successful immunization with recombinant derivatives
of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal
route. Mem Inst Oswaldo Cruz 102: 313–317.
62. Ferreira MU, Katzin AM (1995) The assessment of antibody affinity distribution
by thiocyanate elution: a simple dose-response approach. J Immunol Meth 187:
297–305.
Affinity of Antibodies in Malaria
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32242